NCT06592196 Hepatic Safety of Statin Use in Neurology Inpatients
| NCT ID | NCT06592196 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Yueyang Integrated Medicine Hospital |
| Condition | Statin Adverse Reaction |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2024-08-10 |
| Primary Completion | 2024-10-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2024-08-10 with a primary completion date of 2024-10-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research employs a cross-sectional study and a retrospective cohort study to analyze the liver safety of statin use among inpatients in the neurology department in China from different perspectives. The aim is to supplement evidence-based medicine and provide guidance for the clinical use of statins.
Eligibility Criteria
Inclusion Criteria: 1. Patients hospitalized in the Department of Neurology of Yueyang Hospital from June 2020 to February 2023. 2. Age ≥18 and ≤85 years old, both sexes. 3. Meet the diagnostic criteria of cerebrovascular disease (L1-8B0), headache disease (L1-8A8) and dizziness and vertigo (MB48) in ICD-11. Exclusion Criteria: 1. Incomplete medical history. 2. 1 days ≤ patients with \< 7 days of prior statin use. 3. Patients with malignant tumors (ICD-11 code L1-2A0, L1-2A2, L1-2B5, L1-2E6 diseases) and hematological diseases (ICD-11 code L1-3A0, L1-3B1, L1-3B8 diseases).
Frequently Asked Questions
Who can join the NCT06592196 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Statin Adverse Reaction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06592196 currently recruiting?
Yes, NCT06592196 is actively recruiting participants. Visit ClinicalTrials.gov or contact Shanghai Yueyang Integrated Medicine Hospital to inquire about joining.
Where is the NCT06592196 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06592196 clinical trial?
NCT06592196 is sponsored by Shanghai Yueyang Integrated Medicine Hospital. The trial plans to enroll 2,000 participants.